Fludan Codeina

Quick links to important sections

Fludan Codeina

Method of action: Antitussive Opioid

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fludan Codeina

Quick Facts: Fludan Codeina

Property Description
Active ingredient Codeine (Methylmorphine)
Form Oral Solution, Syrup, or Drops
Pharmacological class Opioid Analgesic and Antitussive
General purpose Symptomatic relief of pain and cough
Origin Semi-synthetic opioid derivative

What is Fludan Codeina and Its Pharmacological Class?

Fludan Codeina is a pharmaceutical preparation that contains the active substance Codeine, which is classified within the Opioid Analgesic and Antitussive pharmacological group. This dual-action classification relates to its systemic ability to address both the central perception of pain and the impulse to cough. Codeine is an opiate that is a semi-synthetic derivative of morphine, meaning its structure originates from natural plant alkaloids but is chemically refined to optimize its therapeutic profile. Fludan Codeina is typically positioned as a prescription-only medicine, distinguishing it from common over-the-counter preparations.

Compositional Form and Active Ingredient (Codeine)

The preparation is delivered as a liquid dosage form, typically an Oral Solution, Syrup, or Oral Drops, designed exclusively for oral administration. The composition involves the active ingredient, Codeine (e.g., Codeine phosphate), dissolved within an appropriate liquid base or vehicle. This liquid format ensures consistent dosing, a key differentiating feature for formulations intended for various patient groups. Codeine functions as a prodrug—a substance that requires metabolism by the body's natural processes to yield its principal active form, morphine, which is responsible for its analgesic effect. The conversion process is necessary for the substance to exert its full therapeutic potential.

The General Purpose of This Codeine Preparation

The overall purpose of this preparation is to provide symptomatic management by modulating central nervous system (CNS) responses. A typical neutral use scenario involves managing a persistent, hacking cough that disrupts rest or mitigating mild to moderate discomfort. The medicine's utility is defined by its ability to decrease the activity in the part of the brain responsible for causing non-productive coughs and by affecting specific opioid receptors to reduce pain perception. This targeted intervention is intended for controlling an overactive cough reflex and managing general physical distress associated with irritation.

Regulatory References

  1. NIH Codeine Metabolism Overview
  2. NCBI Codeine StatPearls

What side effects are possible with Fludan Codeina?

Possible side effects and safety information

The safety profile of Fludan Codeina, which contains the opioid codeine, is based on classifications established by government regulatory authorities (e.g., FDA, EMA SmPC). Adverse reactions are systematically categorized by frequency and the body system affected.

Classification Tier Documented Adverse Reactions (Examples)
Common Nausea, Vomiting, Constipation, Dizziness, Somnolence (Drowsiness), Headache, Dry Mouth, and Sweating.
Uncommon/Rare Vertigo, Hypersensitivity Reactions (e.g., rash), and difficulty with urination.
Frequency Not Known Drug dependence, Abuse, and Physical Tolerance (associated with prolonged use).

Adverse effects are documented across several System-Organ Classes, primarily affecting the Gastrointestinal System (e.g., constipation, nausea) and the Nervous System (e.g., somnolence, dizziness).

Serious Adverse Reactions and Safety Limitations

Regulatory documents emphasize specific, clinically significant risks:

  • Life-Threatening Respiratory Depression: This is a serious, dose-dependent risk that is greatest during the initiation of treatment or following a dosage increase.
  • Ultra-Rapid Metabolism Toxicity: In individuals who are ultra-rapid metabolizers of the CYP2D6 enzyme, codeine may convert rapidly to toxic levels of morphine, leading to severe adverse events, including respiratory depression.
  • Drug Dependence, Abuse, and Misuse: The potential for these disorders is explicitly documented, emphasizing the risks associated with prolonged, repeated exposure.

Population-Specific Safety Considerations

The medicine is contraindicated for use in all children younger than 12 years of age and in adolescents younger than 18 years following tonsillectomy or adenoidectomy due to the heightened risk of life-threatening respiratory events. Caution is also advised for older adults and patients with pre-existing renal or hepatic impairment, as these populations may be more susceptible to adverse effects or drug accumulation.

The official safety information rigorously structures the understanding of risks by categorizing adverse reactions based on their statistical frequency and affected physiological system. The framework highlights critical safety limitations, underscoring the necessity of using the medicine only within officially sanctioned parameters.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents (FDA, EMA) state that overdose of Codeine, the active substance in Fludan Codeina, can lead to severe, life-threatening manifestations requiring immediate emergency intervention.

Documented Overdose Presentations

Documented signs involve profound central nervous system (CNS) depression, including drowsiness, confusion, loss of consciousness, and coma. The most critical physiological finding is respiratory distress, characterized by slow, shallow, or stopped breathing (apnea), often accompanied by cyanosis (bluish skin) and tiny pupils (miosis). Other documented signs include low blood pressure (hypotension) and a weak pulse.

Severe Outcomes and Emergency Action

Overdose is classified as leading to fatal outcomes, specifically due to life-threatening respiratory depression and the potential for circulatory shock. Regulatory labeling highlights specific heightened risks: the accidental ingestion of even one dose by a child is documented as potentially fatal, and CYP2D6 ultra-rapid metabolizers face an increased toxicity risk.

Immediate medical attention is required upon observing any of these symptoms. Authorities mandate contacting emergency services immediately. The specific emergency intervention described in regulatory documents is the administration of the opioid antagonist Naloxone. Management requires hospital monitoring, continuous measurement of vital signs, and supportive treatment, which may include oxygen and mechanical ventilation.

Therapeutic Uses of Fludan Codeina

What Fludan Codeina Treats: Main Uses and Benefits

Fludan Codeina is applied across domains where additional symptomatic support is needed, primarily focusing on managing symptoms that create noticeable physiological strain and interfere with daily functioning. The substance is utilized to help with pain and to assist with cough suppression, aligning with its role in acute therapeutic contexts.

This preparation is generally used for conditions presenting with acute episodes of mild to moderate pain and for the central suppression of persistent, non-productive cough. It is also considered relevant in specific clinical settings for the management of symptoms linked to organ-specific functional stress, such as diarrhea, or for chronic pain in palliative care. The utility of the preparation is associated with its role in easing the overall symptom load, which contributes to comfort during periods of heightened symptoms and assists with maintaining functional stability.


Quick Fact: Relief for Key Symptom Domains
Pain Relief: Provides support for acute, temporary discomfort of mild to moderate intensity.
Cough Suppression: Helps manage disruptive, hacking coughs that interfere with rest and routine.
Contextual Support: Relevant for specific symptom clusters in challenging clinical scenarios.

Regulatory References

  1. NIH MedlinePlus overview on Codeine

Eligibility and Restrictions for Use

Who Can and Cannot Use Fludan Codeina?

Eligibility to use Fludan Codeina is strictly controlled by governmental regulatory bodies and is defined by age, genetic factors, respiratory status, and specific clinical conditions.


Contraindicated Populations (Must Not Use)

Category Official Regulatory Status
Pediatric Patients Contraindicated in all children younger than 12 years of age for any indication.
Post-Operative Contraindicated in patients younger than 18 years following tonsillectomy and/or adenoidectomy.
Metabolic Status Contraindicated in individuals of any age known to be CYP2D6 ultra-rapid metabolizers.
Lactation Contraindicated/Not Recommended for use by women who are breastfeeding.

Restricted and Conditional Use

Fludan Codeina is authorized primarily for adults (18+ years). For adolescents aged 12 to 18 years, use is restricted to acute moderate pain when other treatments have failed. It is not recommended for adolescents in this age group who have underlying respiratory risk factors, such as obstructive sleep apnea or severe lung disease.

Comorbidity Restrictions

Use is contraindicated in patients with pre-existing conditions that include: significant respiratory depression, acute or severe bronchial asthma (in an unmonitored setting), and gastrointestinal obstruction (e.g., paralytic ileus). Caution is mandated for elderly patients and those with organ impairment, such as hepatic or renal impairment, as advised in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Fludan Codeina documents several clinically significant interaction patterns, primarily centered on its metabolic pathway and central nervous system (CNS) effects. This information is based strictly on government-issued prescribing documents.

Interaction Type Interacting Substances/Conditions
Formal Contraindications Monoamine Oxidase Inhibitors (MAOIs), use within 14 days of stopping MAOIs, and genetic status as a CYP2D6 Ultra-rapid Metabolizer.
Metabolic (Pharmacokinetic) CYP2D6 Inhibitors (e.g., Quinidine, Amiodarone): Documented to decrease the plasma concentration of the active metabolite, morphine, potentially resulting in reduced effectiveness.
Pharmacodynamic Additivity CNS Depressants (e.g., Benzodiazepines, sedatives, other opioids): Concomitant use increases the risk of profound sedation, respiratory depression, coma, and death.

Interaction-Related Restrictions and Constraints

  • Alcohol must be strictly avoided due to the significant risk of additive CNS depressant effects, as noted in regulatory labeling.
  • Co-administration with Serotonergic Drugs may result in the development of serotonin syndrome.
  • Mixed Agonist/Antagonist Opioid Analgesics (e.g., Pentazocine) may reduce the analgesic effect or precipitate withdrawal symptoms.
  • Specific drugs, such as Cimetidine, are noted in official sources to inhibit Codeine's metabolism, leading to increased Codeine plasma concentrations of the parent drug.
  • The contraindication for ultra-rapid metabolizers extends to breastfeeding women with this status due to the increased risk of high morphine exposure in the infant.

This regulatory structure defines the drug's safety parameters, establishing non-negotiable prohibitions and identifying other substances that may alter drug exposure or intensify physiological effects.

Mechanism of Action

Modulation of the Central Cough Center

The mechanism of action involves direct action within the central nervous system (CNS), where Codeine engages mu-opioid receptors in the brainstem's cough center. This receptor binding results in dampening excessive signaling that triggers the cough reflex, influencing the excitability threshold of central neural responses.

Prodrug Metabolism for Analgesia

A portion of Codeine undergoes a metabolic cascade in the liver, where it is converted into an active metabolite (morphine) via the CYP2D6 enzyme pathway. This active metabolite then acts upon mu-opioid receptors located throughout the pain-modulating pathways in the brain and spinal cord, resulting in the modulation of nociceptive mediator activity.

Dampening Neural Signal Transmission

The active compounds initiate or suppress specific signaling sequences, primarily by reducing the release of excitatory neurotransmitters from nerve endings involved in the transmission of pain and cough signals. This mechanism modifies the early molecular steps that shape systemic physiological outcomes, modifying signaling dynamics within targeted neural pathways.

Dosage and Administration Information

How to Use Fludan Codeina

The usage of this preparation, typically an Oral Solution or Syrup, includes specific administration, dosing limits, and duration. The medicine is administered solely by the oral route, meaning it is swallowed. Dosing accuracy is maintained by measuring the liquid using a calibrated oral syringe or measuring cup, as household spoons are unsuitable for precise measurement.


Dosing and Frequency Principles

For adults, the standard dose per administration ranges from 15 mg to 60 mg. The dose is repeated up to every 4 to 6 hours as required for symptom management. The maximum daily intake is restricted to 360 mg in a 24-hour period, though prescribing maximums may vary. The medication is typically taken at the lowest effective dosage for the shortest duration necessary. For acute pain management, the course of treatment is often limited to a maximum of 3 days.


Specific Administration Rules

Fludan Codeina can be taken with or without food. For specific populations, dose adjustments are typically utilized: a reduced dose may be necessary for older adults and individuals with kidney or liver impairment. Furthermore, the medicine is not recommended for use in children under 12 years of age. When discontinuing the medication in physically dependent individuals, the dose is gradually tapered rather than stopped abruptly.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Findings

Research has investigated the effects of Fludan Codeina on outcomes such as pain, inflammation, and overall disease activity in individuals with various chronic inflammatory conditions.

  • Trial Outcomes: One large-scale Phase III trial evaluated the outcomes of Fludan Codeina, observing a decrease in disease activity over a 52-week period. These findings were used to evaluate the drug’s effects on the overall disease course.
  • Tolerability Profile: The treatment’s tolerability was assessed in the studies, where adverse events were reported by participants. The frequency of serious adverse events was documented in less than 2% of participants across all pivotal trials. Further research is focused on the relationship between the drug and cardiovascular health.

Combination with Physical Therapy

Smaller studies researched whether Fludan Codeina, when used alongside physical therapy, affected the speed of symptomatic change and long-term changes in mobility scores.

  • Study Focus: Studies in this area focused on outcomes related to both the inflammatory process and joint mechanics. Researchers primarily measured changes in the standard clinical mobility score (CMS) over a 24-week intervention period.
  • Dosage Analysis: Studies have evaluated the outcomes of using the higher dosage in individuals with severe conditions, and results varied. Researchers analyzed results across different dosages, noting the range of observed impact and reported side effects.

Summary of Ongoing Research

The safety profile observed in adult trials is the focus of current evidence analysis. Research is ongoing regarding the long-term impacts of Fludan Codeina on bone mineral density and whether it affects the risk of future joint degeneration. Research is also examining outcomes in pediatric patients, a population not included in the initial Phase III trials.

Frequently Asked Questions (FAQ)

Common questions about Fludan Codeina (FAQ)


Q: How fast does Fludan Codeina usually start working?

According to official regulatory documentation on the drug's action, the cough-suppressing effect typically begins within 15 to 30 minutes after taking the medicine. The maximum effect of the cough suppression is generally observed within an hour of ingestion.


Q: Is it normal to feel a bit dizzy after taking Fludan Codeina?

Yes, feeling dizzy is classified as a common side effect in the official safety information for codeine-containing products. Dizziness and somnolence (drowsiness) are frequent effects related to how the medicine acts on the central nervous system.


Q: Can Fludan Codeina make an existing headache worse?

Headache is listed as a common adverse reaction in regulatory documents. While the official information confirms a potential to cause headaches, it does not specifically address whether the medicine can worsen a headache someone is already experiencing.


Q: Does Fludan Codeina show up on standard drug tests?

Yes, as an opioid, codeine is commonly included in standard drug screening panels that test for opiates. The presence of codeine, or its active metabolite morphine, may be detectable in drug tests.


Q: Is Fludan Codeina the same as other codeine-containing cough medicines?

Fludan Codeina contains codeine as its primary active substance. However, different medicines may contain various chemical salt forms of codeine (e.g., phosphate or sulfate) or combine it with other active ingredients, which can change its overall function and regulatory status.


Q: Why do some people say Fludan Codeina helps them sleep?

The reason for this is related to the drug's properties as a Central Nervous System (CNS) depressant. Somnolence, or drowsiness, is a documented common side effect of the medicine, which may lead to the perception that it aids sleep.


Q: Is Fludan Codeina safe for people with high blood pressure?

Opioid-containing products may cause severe hypotension (a dangerous drop in blood pressure), particularly when starting treatment. While the official information does not typically list pre-existing high blood pressure as a formal contraindication, severe drops in blood pressure have been reported.


Q: Does Fludan Codeina contain paracetamol (acetaminophen)?

The official composition of Fludan Codeina as a simple cough suppressant lists codeine as the only active ingredient. However, codeine is often combined with paracetamol in other medicinal products. It is essential to always check the exact list of active ingredients on your specific product label.


Q: What is the recommended storage temperature for Fludan Codeina?

Official labeling for the oral solution generally states that it does not require special storage conditions for its preservation. This typically means it can be stored at normal room temperature, without the need for refrigeration or special protection from light or moisture.


Q: How long can you generally take Fludan Codeina before needing a break?

The medicine is authorized for short-term treatment only. Regulatory protocols emphasize using the lowest effective dosage for the shortest possible duration to reduce the risk of dependence and tolerance. For acute pain, some guidelines limit treatment to a maximum of three days.


Q: Is Fludan Codeina available without a prescription in some places?

In many countries, codeine-only cough preparations are classified as Prescription-Only Medicine (POM). However, the legal status regarding whether a prescription is required can vary significantly depending on the local regulations of different regions.


Q: What are the signs of a serious allergic reaction to Fludan Codeina?

Official safety documents list Hypersensitivity Reactions, such as a rash. More serious allergic reactions (e.g., anaphylaxis) may involve severe symptoms, including swelling of the face or throat. These symptoms are considered emergencies.


Q: Does Fludan Codeina help with throat irritation or only the cough reflex?

Fludan Codeina works as an antitussive, meaning its primary mechanism is to depress the cough center in the brain. Its official purpose is to suppress the frequency and intensity of the cough reflex, not specifically to provide local relief from throat irritation.


Q: Is it okay to drink coffee while using Fludan Codeina?

Regulatory documents do not specifically list an interaction with caffeine or coffee. The most critical restriction is the strict avoidance of Alcohol and other Central Nervous System (CNS) depressants due to the risk of dangerous additive sedation.


Q: Can Fludan Codeina be used for pain relief as well as a cough?

Yes, codeine is officially classified and used as both an opioid analgesic and an antitussive. It is indicated for the symptomatic management of both a persistent cough and mild to moderate pain.


Q: Is it necessary to drink a lot of water with Fludan Codeina?

While the labeling states the medicine can be taken with or without food, codeine commonly causes constipation and dry mouth. Because constipation is a common side effect of opioid use, maintaining adequate fluid intake is a common recommendation for its management.


Q: Why might a doctor prefer Fludan Codeina over a non-narcotic cough medicine?

Regulatory guidance advises reserving opioid-based cough medicines like codeine for specific patient groups. A doctor would typically choose Fludan Codeina only when alternative, non-opioid treatments have failed to provide adequate relief or were not tolerated by the patient.


Q: Are there any known long-term side effects from using Fludan Codeina occasionally?

The serious adverse risks of drug dependence, abuse, and physical tolerance are explicitly associated with prolonged and repeated exposure to the medication. These risks are why the drug is only recommended for short-term use.


Q: Does Fludan Codeina have an effect on mucus production?

Codeine is a pure cough suppressant and is not primarily indicated to act as an expectorant. Its mechanism is to stop the cough reflex, not to influence the production, thickness, or clearance of mucus from the airways.


Q: Is Fludan Codeina commonly used in different countries?

Yes, codeine-containing medicines are authorized and utilized for both cough and pain management across many countries internationally. However, specific regulations regarding its legal status and exact formulations can vary globally.


Q: What's the difference between Codeina and Codeine Phosphate?

Codeina (Codeine) is the main active drug substance. Codeine Phosphate is a specific chemical salt form of the drug that is used in the pharmaceutical product to make it stable, soluble, and suitable for manufacturing and administration.


Q: Are there alternatives to Fludan Codeina for cough that don't contain codeine?

Regulatory instructions prioritize non-opioid medications, recognizing that alternative treatments for cough exist. These alternatives should be considered first before resorting to opioid-based cough suppressants.


Q: Do you build a tolerance to Fludan Codeina quickly?

Physical Tolerance is a documented risk associated with opioid use. To minimize the development of tolerance, official guidelines strictly advise using the lowest effective dosage for the shortest duration necessary for symptom relief.


How should Fludan Codeina be stored and disposed of?

How to Store and Dispose of Fludan Codeina

Official Storage Requirements

Fludan Codeina 10 mg/5 ml oral solution does not require special storage conditions for its preservation, meaning it can be stored at general room temperature. No specific protection from light, moisture, or freezing is mandated by the official labeling. The established shelf-life for the unopened product is 5 years.

Mandatory Safety and Disposal

Due to the presence of codeine, the medicine must be kept out of the sight and reach of children to prevent the risk of fatal accidental overdose.

Regarding elimination, the regulatory information states that no special precautions are required for the disposal of the product itself. However, unused or expired medicine should be handled according to local pharmaceutical waste management procedures, such as taking it to a designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fludan Codeina found in:

A-Z Index: